Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation

This publication has 14 references indexed in Scilit:

• Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment‐related mortality in stem cell transplantation from unrelated donors using pretransplantin vivoT‐cell depletion with anti‐thymocyte globulin
  British Journal of Haematology, 2001
• The influence of mycophenolate mofetil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantation
  Nephrology Dialysis Transplantation, 2000
• Mycophenolate mofetil for the prophylaxis of acute GVHD in HLA‐mismatched bone marrow transplant patients
  Clinical Transplantation, 2000
• Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients
  Clinical Transplantation, 2000
• Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT
  Bone Marrow Transplantation, 2000
• Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients
  Bone Marrow Transplantation, 1998
• Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes
  Journal of Medical Virology, 1988
• Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease
  Blood, 1986
• Risk Factors for Cytomegalovirus Infection after Human Marrow Transplantation
  The Journal of Infectious Diseases, 1986
• CLINICAL MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONOR,S
  Transplantation, 1974